ASND vs. LEGN, CERE, VKTX, ROIV, JAZZ, ITCI, ELAN, CYTK, IONS, and CTLT
Should you be buying Ascendis Pharma A/S stock or one of its competitors? The main competitors of Ascendis Pharma A/S include Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Viking Therapeutics (VKTX), Roivant Sciences (ROIV), Jazz Pharmaceuticals (JAZZ), Intra-Cellular Therapies (ITCI), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Ionis Pharmaceuticals (IONS), and Catalent (CTLT). These companies are all part of the "pharmaceutical preparations" industry.
Legend Biotech (NASDAQ:LEGN) and Ascendis Pharma A/S (NASDAQ:ASND) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, community ranking, profitability, valuation and risk.
Legend Biotech currently has a consensus price target of $82.64, indicating a potential upside of 79.70%. Ascendis Pharma A/S has a consensus price target of $173.88, indicating a potential upside of 27.87%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Legend Biotech is more favorable than Ascendis Pharma A/S.
Legend Biotech has higher earnings, but lower revenue than Ascendis Pharma A/S. Legend Biotech is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.
70.9% of Legend Biotech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Ascendis Pharma A/S has a net margin of -152.68% compared to Ascendis Pharma A/S's net margin of -181.75%. Ascendis Pharma A/S's return on equity of -37.19% beat Legend Biotech's return on equity.
Legend Biotech has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.
Ascendis Pharma A/S received 352 more outperform votes than Legend Biotech when rated by MarketBeat users. Likewise, 65.65% of users gave Ascendis Pharma A/S an outperform vote while only 63.33% of users gave Legend Biotech an outperform vote.
In the previous week, Ascendis Pharma A/S had 14 more articles in the media than Legend Biotech. MarketBeat recorded 16 mentions for Ascendis Pharma A/S and 2 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 0.36 beat Ascendis Pharma A/S's score of 0.01 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.
Summary
Legend Biotech and Ascendis Pharma A/S tied by winning 9 of the 18 factors compared between the two stocks.
Get Ascendis Pharma A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ascendis Pharma A/S Competitors List
Related Companies and Tools
